Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Edward Schwarz, PhD
Co-Founder and Chief Scientific Advisor
Telephus’ scientific founder is Dr. Edward Schwarz, a thought leader in the field of musculoskeletal health and the Richard and Margaret Burton Distinguished Professor in Orthopaedics in the Department of Orthopaedics at the University of Rochester School of Medicine and Dentistry. As director of the Center for Musculoskeletal Research at the University of Rochester Medical Center, he has developed multiple proprietary preclinical models to study implant-associated osteomyelitis and other aspects of bone health. A key opinion leader and consultant to global pharmaceutical and biotechnology companies, Dr. Schwarz holds multiple patents in the areas of bone health and therapies for joint disease. Dr. Schwarz received his PhD in immunology from the Albert Einstein College of Medicine, his BS in biology from the Worcester Polytechnic Institute, and completed his postdoctoral work at the Salk Institute.
Chief Financial Officer
Mr. Zaniboni is a founder of Global Source Ventures (GSV), has over 25 years of experience as a finance executive in the life sciences industry and has served as CFO of six companies including AviaraDx, Awarepoint, Sequenom (NASDAQ: SQNM), Sorrento Therapeutics (NASDAQ: SRNE), Trovagene (NASDAQ: TROV), and XIFIN. He was responsible for financial planning & strategy, and led funding and exit transactions. In the aggregate, Steve raised over $600 million through venture funding, debt financing, and IPO proceeds and completed four M&A transactions. Mr. Zaniboni was a practicing CPA with Arthur Andersen and holds a BS in accounting from Boston University and MBA from Boston College.
Michael Wood, MBA
Mr. Wood has over 20 years of healthcare and business experience. Prior to advising Telephus, he was vice president of corporate development & operations at Crinetics Pharmaceuticals, where he led the company’s $40M series A and managed operations. Prior to this role, he worked in business development at aTyr Pharma and Orexigen, where he co-led the company’s $1 billion development and commercialization deal with Takeda. In addition, he worked in sales, marketing, and business development at Abbott Laboratories, where he earned the company’s top national sales award and helped launch two blockbuster drugs. Prior to Abbott, he worked in management consulting, investment banking, and scientific research. He holds a BS in molecular and cell biology, summa cum laude and phi beta kappa, from the University of California, Berkeley, where he was a member of its national champion rowing team, and MBA from the University of Chicago.
Robert Geckeler, MBA
Mr. Geckeler has 25 years of pharmaceutical industry experience spanning a wide range of therapeutic areas and product formats. He has managed and led product development programs at all stages, from proof-of-concept to registration and launch, as well as life-cycle management for a number of marketed therapeutics. Mr. Geckeler previously served as vice president of development at Xenome Ltd., where he had broad responsibility for global operations supporting clinical-stage product development, was team leader for the company’s most advanced therapeutic program, and represented the company on multiple early-stage collaborations. Before that, he held executive and project leadership positions at Elan Pharmaceuticals, Arena Pharmaceuticals, Avera Pharmaceuticals, and PAREXEL International. Mr. Geckeler holds a BA in biology from Washington University in St. Louis, and an MBA from San Diego State University.
Barry Rosenblatt, PhD
Dr. Rosenblatt is an expert in the chemistry and manufacturing controls (CMC) of biotherapeutics. His nearly 30 years of experience at Centocor, Johnson and Johnson, and Charles River Laboratories includes the design and implementation of CMC programs for a number of highly successful, marketed monoclonal antibody products. In addition to leading the process development programs for these products and others, he was instrumental in the preparation of the CMC sections for the respective Biologics License Applications leading to their approval. Since 2004, he has served as president of SME Biotech Consulting. Dr. Rosenblatt holds a PhD in cell biology and immunology from the Albert Einstein College of Medicine, and a BA in biochemistry from Columbia University.
Ms. Peterson has over 30 years of pharmaceutical industry experience, and possesses significant strengths in US and ex-US regulatory affairs strategy. She is founder and general partner of DSC Associates, who provide regulatory and clinical strategy consulting services to the pharmaceutical, biotechnology, and medical device industries. Ms. Peterson previously served as vice president of regulatory affairs at FeRx, and held senior managerial positions in pharmaceutical development and regulatory affairs at Amylin Pharmaceuticals, with additional experience from both the therapeutics and diagnostics divisions at Hybritech Incorporated.
Lynne Rollins, MBA
Ms. Rollins brings to Telephus more than 30 years of experience in healthcare-related finance and business development. She has served as chief financial officer at a number of start-up pharmaceutical and medical device companies, including Sonexa Therapeutics, Calixa Therapeutics, Tensys Medical, Inspiration Biopharmaceuticals, Syndax Pharmaceuticals, Orexigen Therapeutics, Novalar Pharmaceuticals, and Novacea. Ms. Rollins also held executive roles in finance at Ascenta Therapeutics and, earlier in her career, within Baxter Healthcare’s cardiopulmonary business. She also currently serves as chief financial officer for Domain Russia Investments, a partnership of the venture capital firm Domain Associates designed to foster innovation in the Russian health sciences sector. Ms. Rollins received her BS in finance from California State University and her MBA from Pepperdine University.
Antonius ‘Toni’ Schuh, PhD
Dr. Schuh is a founder of Global Source Ventures. He has over 20 years of executive leadership experience in the biotechnology, healthcare, and life sciences industries and has served as chief executive officer of five life sciences companies, including Arcturus Bioscience, AviaraDx (now bioTheranostics), Sequenom (NASDAQ: SQNM), Sorrento Therapeutics (NASDAQ: SRNE) and Trovagene (NASDAQ: TROV). In each case he developed the company’s strategy based on a focused value proposition, oversaw the execution of such strategy, and secured funding to achieve transforming milestones, including multiple product launches. He delivered significant returns for investors at exit (public offering or acquisition). Toni is a certified pharmacist and earned his PhD in pharmaceutical chemistry from the University of Bonn, Germany.
Mike Maloney, MD
Dr. Maloney is professor of orthopaedics at the University of Rochester Medical Center (URMC). A board-certified orthopaedic surgeon, he is also division chief of the URMC Orthopaedics’ University Sports Medicine program, where his clinical practice includes reconstructive surgery of the knee, shoulder, and elbow, and arthroscopy of the knee, shoulder, and elbow for patients of all age groups. A consulting orthopedic surgeon for several internationally-recognized professional sports organizations, Dr. Maloney has authored numerous medical journal articles on topics such as the biomechanics of the injured and uninjured knee, shoulder injuries and techniques for repair and experimental gene therapy for cartilage repair. Dr. Maloney earned his undergraduate and medical degrees from Georgetown University. He completed his orthopaedic surgical residency at URMC Orthopaedics and the Sports Medicine Fellowship at the Kerlan-Jobe Orthopaedic Clinic in Los Angeles, California.
Seth Zeidman, MD
Dr. Zeidman is a board-certified neurological surgeon in private practice at the Rochester Brain & Spine Neurosurgery and Pain Management clinic in Rochester, New York where he is president and founder of the practice. He is the former director of complex spinal neurosurgery at the University of Rochester—Strong Memorial Hospital. Prior to relocating to Rochester in 1999, he served in the US Army as director of neurosurgical spinal surgery at the Walter Reed Army Medical Center in Washington, DC. Prior to entering into military service, Dr. Zeidman served as an assistant chief of service of neurosurgery at the Johns Hopkins Hospital. A globally-recognized expert in spinal surgery, Dr. Zeidman attended Duke University both as an undergraduate, where he graduated with honors from Trinity College, and for medical school. His MD was awarded from Duke University School of Medicine where he was given special recognition for excellence in internal medicine and pathology. Dr. Zeidman completed his internship in general surgery and a neurosurgical residency at the Johns Hopkins Hospital prior to completing a fellowship in neurosurgical research with an emphasis on brain and spinal tumors at the National Institutes of Health in Bethesda Maryland. He also completed a clinical spinal surgery fellowship.
David Leve, JD, MBA
Mr. Leve has over 20 years of experience in the private practice of law. The founder and principal of Leve Law Offices, LLC in Rochester, New York, Mr. Leve has represented clients ranging from individuals and closely held businesses to major banking institutions across a wide variety of matters including debt and equity finance; business structuring and governance; real estate transactions, development and finance, including structured finance and syndication; regulatory management and compliance; and commercial litigation direction and management. He began his legal career with Nixon Peabody LLP in Rochester and has served as a board director and manager of several private companies. Mr. Leve was educated at Yale University (BA) and the State University of New York at Buffalo (JD, MBA).
William Boyle, PhD
Dr. Boyle is Vice President of Translational Medicine of BioAtla, LLC, and is an Associate Professor of Medicine at UCLA David Geffen School of Medicine. Previously, Dr. Boyle founded AnaptysBio, Inc, in 2005 as an antibody therapeutics company based on harnessing the use of somatic hypermutation for antibody discovery and optimization. (NASDAQ:ANAB) and served as its Chief Scientific Officer and President. Prior to AnaptysBio, Dr. Boyle was at Amgen for over eleven years, where as Director of Discovery Research, he led the preclinical and clinical development of osteoprotegerin, a natural endogenous factor protecting bone from resorption. His research in this area helped to define the RANK-RANKL signaling pathway and led to the isolation and characterization of Prolia® and Exgeva® (denosumab), the first antibody treatment for osteoporosis and the treatment of skeletal related events in cancer, for which Dr. Boyle is an inventor. Dr. Boyle earned his B.S. and M.S. in biology, as well as his Ph.D. in experimental pathology at UCLA. Dr. Boyle was a Howard Hughes Medical Institute postdoctoral fellow of the Life Sciences Research Foundation at the Salk Institute of Biological studies.
Richard Proctor, MD
Dr. Proctor is a Professor Emeritus in the Department of Medicine and Microbiology at UW-Madison. Previously, he was the Global Director for Infectious Diseases for Antibiotics and Antifungals at Merck. Dr. Proctor is a leading expert on mechanisms of bacterial pathogenesis in infectious disease. He serves as a member of the scientific advisory board at AmebaGon, Inc. He serves on a number of panels addressing emerging antibiotic resistance and served as President of the Wisconsin Chapter of the Infectious Diseases Society of America. He was a founding member of the International Endotoxin Society and the cofounder of the Staphylococcal Diseases Gordon Conference. Prior to his appointment at the University of Wisconsin, Dr. Proctor earned his B.S. and M.D. at the University of Michigan.